
The FDA has granted approval to piflufolastat F 18 injection, a prostate-specific membrane antigen–targeted positron emission tomography imaging agent, to identify patients who may have metastasis or recurrence of prostate cancer.

The FDA has granted approval to piflufolastat F 18 injection, a prostate-specific membrane antigen–targeted positron emission tomography imaging agent, to identify patients who may have metastasis or recurrence of prostate cancer.

Rajneesh Nath, MD, discusses outcomes for older patients with acute myeloid leukemia.


Idecabtagene vicleucel is now an available treatment option for some patients with relapsed or refractory multiple myeloma who are being treated at Seattle Cancer Care Alliance.

In an interview with Targeted Oncology, Risa Wong, MD, discussed platinum versus non-platinum containing chemotherapy as a later-line treatment for metastatic urothelial carcinoma.

The investigational CDK4/6 ARK5 inhibitor, ON 123300, has been dosed in the first time in a patient whose is enrolled in a phase 1 trial of ON 123300 for the treatment of advanced cancers.

Mantle cell lymphoma cell lines with intrinsic resistance to BTK inhibitors displayed anti-tumor activity on treatment with tazemetostat as monotherapy or in combination with zanubrutinib, according to data from a preclinical analysis.

Marie E. Cabanillas, MD, an oncologic endocrinologist at the University of Texas MD Anderson Cancer Center, discusses current unmet needs in advanced or metastatic TRK fusion-Positive thyroid cancer.

The FDA has accepted the biologic license application (BLA) for ublituximab in combination with umbralisib for the treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Deeper remissions in patients with newly diagnosed, high-risk/secondary acute myeloid leukemia may be achieved with CPX-351 treatment and lead to improvement in overall survival, according to post hoc analyses of a phase 3 study.

The combination of ibrutinib and venetoclax showed a favorable benefit-risk profile in patients with relapsed or refractory chronic lymphocytic leukemia treated in the VISION/HOVON 141.

The FDA has granted breakthrough therapy designation to the combination of VS-6766 and defactinib for the treatment of all patients with recurrent low-grade serous ovarian cancer.

A biologic license application has been submitted to the FDA for the PD-1 monoclonal antibody drug penpulimab for the third-line treatment of metastatic nasopharyngeal carcinoma.

Nadia Harbeck, MD, PhD, discusses how the monarchE trial, which evaluated the efficacy of endocrine therapy with or without abemaciclib, will change breast cancer treatment.

On the second day of a 2-day meeting of the Pediatric Oncology Subcommittee of the FDA’s Oncologic Drug Advisory Committee, members and guests brought into question the role of real-world data in regulatory decision-making for pediatric oncology drugs.

A retrospective analysis showed there were more durable survival outcomes with avapritinib versus other tyrosine kinase inhibitors in adult patients with gastrointestinal stromal tumors and a platelet-derived growth factor receptor A D842V mutation

After receiving a complete response letter by the FDA, an approval application for ropeginterferon alfa-2b for treatment for patients with polycythemia vera. has been resubmitted to the FDA.

The FDA has granted approval to amivantamab-vmjw for the frontline treatment of adult patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.

Tislelizumab, an anti-PD-1 antibody combined with gemcitabine and cisplatin demonstrated improvement in progression-free survival (PFS) compared with chemotherapy as first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer, meeting the primary end point of the phase 3 RATIONALE 309 trial, according to a press release by BeiGene, Ltd.

The FDA granted approval to adjuvant nivolumab as treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy.

A standing question for oncologists is what to do for patients with tumors smaller than 2 cm. The question led to a debate on whether to administer neoadjuvant chemotherapy to patients with T1c hormone receptor–negative, HER2-positive breast cancer during the 38th Annual Miami Breast Cancer Conference.

In an interview with Targeted Oncology, Sergio A. Giralt, MD, discussed recent data from the study.

Targeting different pathways may dramatically reduce the risk of resistance emergence and improve outcomes.

PFS Doubles for Advanced Melanoma Patients Treated with Relatlimab Plus Nivolumab.

The FDA has granted a fast track designation to the autologous chimeric antigen receptor T-cell agent, AIC100, for the treatment of patients with anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.

The FDA has accepted a supplemental new drug application for zanubrutinib for the treatment of adult patients with marginal zone lymphoma who have received 1 prior anti-CD20-based therapy. The agent was also granted priority review, with a Prescription Drug User Fee Act target action date of September 19, 2021.

In an interview with Targeted Oncology, Thomas Marron, MD, PhD, discussed neoadjuvant cemiplimab for the treatment of hepatocellular carcinoma.

In an interview with Targeted Oncology, Naseema Gangat, MD, MBBS, discussed her recommendations for managing pregnant patients with myeloproliferative neoplasms.

The FDA has accepted a biologics license application or sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with nonsquamous non-small cell lung cancer.

The first patient has been dosed in a study designed to evaluate the safety and feasibility of IL13Rα2 chimeric antigen receptor T cell therapy for the treatment of leptomeningeal brain tumors, such as glioblastoma, ependymoma, and medulloblastoma.